UCB (EBR:UCB) UCB Media Room: UCB Announces Launch of Nile AI, Inc.

Directive transparence : information réglementée

13/01/2021 07:01
https://mb.cision.com/Public/18595/3267112/862386e4a9cd3b53_800x800ar.jpg ** UCB Announces Launch of Nile AI, Inc., a Digital Health Company Set to T= ransform the Course of Epilepsy ------------------------------------------------------------ =C2=B7 Nile is developing a digital epilepsy care management platform and b= ringing together data to make the epilepsy journey predictable. =C2=B7 UCB invested =E2=82=AC25 million ($29.3 million) and as majority sha= reholder, will sit on the Board of Directors of Nile with future opportunit= ies to acquire insights and data from Nile=E2=80=99s platform. Brussels (Belgium) and Atlanta, Ga. 13 January 2021 =E2=80=93 7:00a (CET) -= UCB today announced the launch of Nile AI, Inc., a new independent company= created to improve care for people living with epilepsy, their caregivers,= and healthcare providers (HCPs). Nile was founded with a clear mission in = mind: to make the journey of every epilepsy patient predictable. To that en= d, Nile is developing an epilepsy care management platform that serves as a= digital extension of the healthcare provider (HCP) and provides patients w= ith peace of mind between consultations, with the ultimate goal of shorteni= ng the path to optimal treatment.=C2=A0 UCB=E2=80=99s =E2=82=AC25 million ($29.3 million) investment is part of UCB= =E2=80=99s overall commitment to improving the lives of people living with = severe diseases, including epilepsy, as digital technologies continue to ch= ange and impact the way healthcare is delivered. As a majority shareholder,= UCB will will sit on the Board of Directors of Nile with future opportunit= ies to acquire insights and data from Nile=E2=80=99s platform. =E2=80=9CUCB has a deep understanding of epilepsy and the challenges that p= eople living with the disease face every day, including how patients commun= icate with their healthcare providers. We think Nile=E2=80=99s platform can= provide valuable insights and foster a better care management experience f= or people living with epilepsy,=E2=80=9D said Charl Van Zyl, Executive Vice= President, Head of Neurology Solutions and International Markets, UCB. =E2= =80=9CThe launch of Nile is a further illustration of UCB=E2=80=99s commitm= ent and leadership in epilepsy, and how digital platforms can help provide = transformational outcomes and experiences for patients.=E2=80=9D=C2=A0 Nile=E2=80=99s digital platform consists of a patient app and HCP portal. T= he patient app is an intuitive, smart tool for patients to feel connected w= ith their care team, learn about their journey, and understand their progre= ss. The HCP portal shows the status of their patients at a glance, virtuall= y informs and supports their patients in between appointments, and allows d= ata-driven decisions on treatment and care. Nile is currently testing the p= latform in usability studies with two U.S. healthcare systems, Massachusett= s General Hospital and Michigan State University Healthcare. The platform i= s expected to be commercially available in 2021.=C2=A0 =E2=80=9CWe know that patients suffering from epilepsy struggle with the un= predictable nature of their lives,=E2=80=9D said Dr. Leo Petrossian, Chief = Executive Officer of Nile AI, Inc. =E2=80=9CEvery single day they awake unc= ertain of what they can expect. At Nile, we believe that all of the data to= predict the path of an epilepsy patient exists, though it is fragmented an= d disconnected. We are building a comprehensive care management system for = addressing this uncertainty in the lives of people suffering from epilepsy.= =E2=80=9D Nile is a collaboration-driven organization and is welcoming partners in th= is mission. To create lasting impact in the lives of patients, Nile aims to= identify the essential work in the epilepsy ecosystem, align efforts acros= s various fields, and amplify them under one roof. The company is headquart= ered in Los Angeles, California. For more information, visit www.Nile.ai. UCB supports new digital platforms in its mission to transform the way care= is delivered and accelerate better outcomes for people living with severe = diseases as part of its digital business transformation now and in the futu= re.=C2=A0 About UCB UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company = focused on the discovery and development of innovative medicines and soluti= ons to transform the lives of people living with severe diseases of the imm= une system or of the central nervous system. With more than 7 500 people in= approximately 40 countries, UCB generated revenue of =E2=82=AC 4.9 billion= in 2019. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Tw= itter: @UCB_news About UCB in Epilepsy=C2=A0 UCB has a rich heritage in epilepsy with over 20 years of experience in the= research and development of anti-epileptic drugs. As a company with a long= -term commitment to epilepsy research, our goal is to address unmet medical= needs. Our scientists are proud to contribute to advances in the understan= ding of epilepsy and its treatment. We partner and create super-networks wi= th world-leading scientists and clinicians in academic institutions, pharma= ceutical companies, and other organizations who share our goals. At UCB, we= are inspired by patients, and driven by science in our commitment to suppo= rt patients with epilepsy. About Nile Nile is an independent company that seeks to improve care for people living= with epilepsy, their caregivers and healthcare providers. Nile is on a mis= sion to make the journey of every epilepsy patient predictable. Its digital= epilepsy care management platform will provide tools for people living wit= h epilepsy and providers to progress to data-driven, personalized care. Nil= e is a collaboration-driven organization and is welcoming partners in this = mission. For more information, visit www.Nile.ai and email info@Nile.ai. For further information, UCB: UCB Communications Erica Puntel Digital Business Transformation, UCB T 404.938.5359, erica.puntel@ucb.com =C2=A0=C2=A0 Laurent Schots Global Communications, UCB T: +32 (0)2 559 92 64, laurent.schots@ucb.com Investor Relations Antje Witte Investor Relations, UCB =C2=A0=C2=A0 T +32.2.559.94.14, antje.witte@ucb.com =C2=A0=C2=A0 Isabelle Ghellynck Investor Relations, UCB T+32.2.559.9588, isabelle.ghellynck@ucb.com For further information, Nile: Nile AI, Inc. T 818.351.9744, info@Nile.ai ### Forward looking statements =E2=80=93 UCB This press release contains forward-looking statements based on current pla= ns, estimates and beliefs of management. All statements, other than stateme= nts of historical fact, are statements that could be deemed forward-looking= statements, including estimates of revenues, operating margins, capital ex= penditures, cash, other financial information, expected legal, political, r= egulatory or clinical results and other such estimates and results. By thei= r nature, such forward-looking statements are not guarantees of future perf= ormance and are subject to risks, uncertainties and assumptions which could= cause actual results to differ materially from those that may be implied b= y such forward-looking statements contained in this press release. Importan= t factors that could result in such differences include: changes in general= economic, business and competitive conditions, the inability to obtain nec= essary regulatory approvals or to obtain them on acceptable terms, costs as= sociated with research and development, changes in the prospects for produc= ts in the pipeline or under development by UCB, effects of future judicial = decisions or governmental investigations, product liability claims, challen= ges to patent protection for products or product candidates, changes in law= s or regulations, exchange rate fluctuations, changes or uncertainties in t= ax laws or the administration of such laws and hiring and retention of its = employees.=C2=A0 UCB is providing this information as of the date of this press release and = expressly disclaims any duty to update any information contained in this pr= ess release, either to confirm the actual results or to report a change in = its expectations. There is no guarantee that new product candidates in the = pipeline will progress to product approval or that new indications for exis= ting products will be developed and approved. Products or potential product= s which are the subject of partnerships, joint ventures or licensing collab= orations may be subject to differences between the partners. Also, UCB or o= thers could discover safety, side effects or manufacturing problems with it= s products after they are marketed. Moreover, sales may be impacted by inte= rnational and domestic trends toward managed care and health care cost cont= ainment and the reimbursement policies imposed by third-party payers as wel= l as legislation affecting biopharmaceutical pricing and reimbursement. =C2=A0 GenericFile UCB - Nile - Press Release - FINAL (https://mb.cision.com/Public/18595/3267= 112/b2fff860e203747c.pdf)=0D =0D ______________________=0D If you would rather not receive future communications from UCB SA, please g= o to https://eu.vocuspr.com/OptOut.aspx?2973226x20421x58118x1x6868579x24000= x6&Email=3Dregnews%40symexglobal.com.=0D UCB SA, All=C3=A9e de la Recherche, 60 ., Brussels, . B - 1070 Belgium=

15/01/2021 07:02
13/01/2021 07:01
09/01/2021 20:01
18/12/2020 20:01
04/12/2020 20:05
20/11/2020 20:05
17/11/2020 13:04
12/11/2020 07:05
10/11/2020 20:04
06/11/2020 14:07